ERIS Lifescience

Has ERIS Lifescience declared dividend?

ERIS Lifesciences Ltd has declared a 735% dividend, amounting to ₹7.35 per share, with an ex-date of February 13, 2025. The company has shown strong price returns over various periods, indicating robust performance and potential shareholder value.

ERIS Lifesciences Ltd has declared a 735% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 735%<BR>- Amount per share: 7.35<BR>- Ex-date: 13 Feb 25<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.46%, the dividend return was 0.49%, resulting in a total return of 11.95%.<BR><BR>Over the past year, the price return reached 67.08%, with a dividend return of 0.73%, leading to a total return of 67.81%.<BR><BR>For the two-year period, the price return was 154.22%, the dividend return was 1.09%, culminating in a total return of 155.31%.<BR><BR>In the three-year span, the price return stood at 146.99%, the dividend return was 2.31%, resulting in a total return of 149.3%.<BR><BR>Over the last four years, the price return was 127.14%, with a dividend return of 2.95%, giving a total return of 130.09%.<BR><BR>Finally, in the five-year period, the price return was 223.91%, the dividend return was 5.85%, leading to a total return of 229.76%.<BR><BR>Overall, ERIS Lifesciences has declared a significant dividend, which, combined with strong price returns over multiple periods, indicates a robust performance and potential for shareholder value.

Who are the peers of the ERIS Lifescience?

ERIS Lifescience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca, Alembic Pharma, Concord Biotech, Jubilant Pharma, and Caplin Point Lab. ERIS Lifescience has a 1-year return of 75.46%, outperforming its peers, with Divi's Lab leading at 51.96% and Cipla at 0.86%.

Peers: The peers of ERIS Lifescience are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, Alembic Pharma, Concord Biotech, Jubilant Pharmo, and Caplin Point Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, and Average management risk is noted at Jubilant Pharmo. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, ERIS Lifescience, Alembic Pharma, and the rest. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, while Good capital structure is found at Torrent Pharma, and Average capital structure is seen at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Cipla at 0.86%. ERIS Lifescience's 1-year return of 75.46% is significantly higher than both. Additionally, Alembic Pharma and Jubilant Pharmo have negative six-month returns.

Who are in the management team of ERIS Lifescience?

As of March 2022, the management team of ERIS Lifescience includes Amit Indubhushan Bakshi (CMD & Executive Director), Kaushal Kamlesh Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan (Executive Director/WTD/Chairman), and four Independent Non-Executive Directors: Sujesh Vasudevan, Prashant Gupta, Rajeev Narotam Dalal, and Kalpana Unadkat. They oversee the company's strategic direction and governance.

As of March 2022, the management team of ERIS Lifescience includes the following individuals:<BR><BR>1. Amit Indubhushan Bakshi - CMD & Executive Director<BR>2. Kaushal Kamlesh Shah - WTD & Executive Director<BR>3. Inderjeet Singh Negi - WTD & Executive Director<BR>4. Krishnakumar Vaidyanathan - Executive Director / WTD / Chairman<BR>5. Sujesh Vasudevan - Independent Non-Executive Director<BR>6. Prashant Gupta - Independent Non-Executive Director<BR>7. Rajeev Narotam Dalal - Independent Non-Executive Director<BR>8. Kalpana Unadkat - Independent Non-Executive Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

What does ERIS Lifescience do?

Eris Lifesciences Ltd manufactures and markets pharmaceutical products and is classified as a Large Cap company. As of March 2025, it reported net sales of ₹7,053 Cr and a net profit of ₹938 Cr.

Overview: <BR>Eris Lifesciences Ltd is engaged in the manufacturing and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History: <BR>Eris Lifesciences Limited was incorporated on January 25, 2007, and changed its name to 'Eris Lifesciences Private Limited' on February 9, 2007. The company was converted into a Public Limited Company and rebranded as 'Eris Lifesciences Limited' on February 2, 2017. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 7,053 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 938 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 24,168 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 68.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: 0.79 <BR>Return on Equity: 12.35% <BR>Price to Book: 8.31 <BR><BR>Contact Details: <BR>Address: 8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-30451000 <BR>Email: complianceofficer@erislifesciences. <BR>Website: http://www.eris.co.in

Who are the top shareholders of the ERIS Lifescience?

The top shareholders of ERIS Lifescience include promoter Amit Indubhusan Bakshi with 42.84%, mutual funds holding 16.59%, foreign institutional investors at 8.43%, and the highest public shareholder, Lilac Investments Limited, with 8.79%. Individual investors collectively own 9.16% of the shares.

The top shareholders of ERIS Lifescience include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Amit Indubhusan Bakshi, owning 42.84% of the company. Additionally, mutual funds hold 16.59% of the shares, represented by 22 schemes, while foreign institutional investors (FIIs) account for 8.43% through 135 different entities. The highest public shareholder is Lilac Investments Limited, which holds 8.79%. Individual investors collectively own 9.16% of the shares.

How big is ERIS Lifescience?

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, with recent Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr. The company reports Shareholder's Funds of 2,854.36 Cr and Total Assets of 6,744.13 Cr.

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr.<BR><BR>The latest annual period shows Shareholder's Funds of 2,854.36 Cr and Total Assets amounting to 6,744.13 Cr.

Is ERIS Lifescience overvalued or undervalued?

As of September 5, 2025, ERIS Lifescience is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 60.82 and EV to EBITDA ratio of 24.71, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 26.09% that underperformed against the Sensex's 3.29%.

As of 5 September 2025, the valuation grade for ERIS Lifescience has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 60.82, an EV to EBITDA ratio of 24.71, and a PEG ratio of 37.14, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla is more attractively valued with a PE of 23.25 and an EV to EBITDA of 16.37. The high valuation metrics of ERIS Lifescience suggest that it is trading at a premium compared to its peers, which reinforces the conclusion of being overvalued. Notably, despite recent stock performance showing a 26.09% return year-to-date, it has underperformed against the Sensex's 3.29% return during the same period.

How has been the historical performance of ERIS Lifescience?

ERIS Lifescience has shown significant growth, with net sales increasing from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025, and operating profit rising from 376.60 Cr to 1,035.56 Cr. However, profit after tax fluctuated, peaking at 406.11 Cr in March 2022 and declining to 351.84 Cr by March 2025.

Answer:<BR>The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020.<BR><BR>Breakdown:<BR>ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.

Is ERIS Lifescience technically bullish or bearish?

As of December 1, 2025, ERIS Lifescience's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bearish MACD and KST indicators, while moving averages suggest a slight bullish stance on the daily chart.

As of 1 December 2025, the technical trend for ERIS Lifescience has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bearish on both weekly and monthly time frames, while the Bollinger Bands show a bearish signal weekly but mildly bullish monthly. The moving averages indicate a mildly bullish stance on the daily chart, contrasting with the bearish signals from the KST on both weekly and monthly time frames. The Dow Theory suggests a mildly bullish trend on the weekly chart, but there is no clear trend on the monthly. Overall, the lack of strong bullish or bearish signals and the sideways trend indicate a neutral stance with no clear strength in either direction.

When is the next results date for ERIS Lifesciences Ltd?

The next results date for ERIS Lifesciences Ltd is 13 February 2026.

The next results date for ERIS Lifesciences Ltd is scheduled for 13 February 2026.

Are ERIS Lifesciences Ltd latest results good or bad?

ERIS Lifesciences Ltd's latest results show record net sales growth of 11% year-on-year, but significant margin compression led to a 17% decline in net profit quarter-on-quarter. While revenue growth is positive, the decline in profitability raises concerns about operational efficiency, suggesting investors should proceed with caution.

ERIS Lifesciences Ltd's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹807.45 crores in Q3 FY26, reflecting an 11.00% increase year-on-year and a 1.90% rise quarter-on-quarter. This indicates solid revenue growth, which is a positive sign.<BR><BR>However, the results also show significant margin compression. The operating margin decreased to 35.16% from 36.48% in the previous quarter, and the profit after tax (PAT) margin fell sharply to 13.59% from 17.02%. This led to a 17.03% decline in consolidated net profit to ₹99.72 crores compared to the previous quarter, although it is up 19.05% year-on-year.<BR><BR>The sequential decline in profitability raises concerns about operational efficiency and cost management, especially in a competitive pharmaceutical sector facing pricing pressures. Analysts are now reassessing the company's near-term prospects due to this margin erosion and the flat financial trend classification.<BR><BR>Overall, while the revenue growth is commendable, the decline in margins and profit suggests that the company is facing challenges that could impact its future performance. Investors may want to approach with caution, considering both the growth potential and the current operational hurdles.

Should I buy, sell or hold ERIS Lifesciences Ltd?

Which are the latest news on ERIS Lifescience?

Why is ERIS Lifesciences Ltd falling/rising?

As of 08-May, ERIS Lifesciences Ltd's stock price is rising at 1,386.75, with a recent increase of 3.1 (0.22%). The stock has shown strong short-term performance, significantly outperforming the Sensex, driven by increased investor interest and positive trading indicators.

As of 08-May, ERIS Lifesciences Ltd is experiencing a rise in its stock price, currently at 1,386.75, with a change of 3.1 (0.22%) upward. The stock has shown a strong performance over the past week, with a return of +4.84%, significantly outperforming the Sensex, which only increased by +0.54%. Additionally, the stock has gained 5.98% over the last six consecutive days, indicating a positive momentum.<BR><BR>Investor participation has also increased, as evidenced by a delivery volume of 1.01 lacs on 07 May, which is up by 159.82% compared to the 5-day average. This rising interest suggests that more investors are willing to buy into the stock, contributing to its upward price movement. Furthermore, the stock is currently trading above its 5-day, 20-day, and 50-day moving averages, which typically signals bullish sentiment among traders.<BR><BR>Despite some long-term concerns, such as a poor growth rate in operating profit and underperformance compared to the broader market over the past year, the current short-term indicators and rising investor interest are driving the stock's price higher. The company's high management efficiency, indicated by a ROCE of 16.70%, and strong institutional holdings at 26.75% also support the stock's positive outlook in the near term.